Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Autor: Stuart, ASV, Shaw, RH, Liu, X, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Darton, T, Dinesh, T, Duncan, CJA, England, A, Faust, SN, Ferreira, DM, Finn, A, Goodman, AL, Green, CA, Hallis, B, Heath, PT, Hill, H, Horsington, BM, Lambe, T, Lazarus, R, Libri, V, Lillie, PJ, Mujadidi, YF, Payne, R, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Screaton, GR, Singh, N, Turner, DPJ, Turner, PJ, Vichos, I, White, R, Nguyen-Van-Tam, JS, Snape, MD, Com-COV2 Study Group

Publikováno v: Lancet (London, England)
Snape, M D 2022, ' Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2) : a single-blind, randomised, phase 2, non-inferiority trial ', Lancet, vol. 399, no. 10319, pp. 36-49 . https://doi.org/10.1016/S0140-6736(21)02718-5

Background Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72507942631237263460b52b50669b5
https://doi.org/10.1016/s0140-6736(21)02718-5

Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis

Autor: Hart, WS, Miller, E, Andrews, NJ, Waight, P, Maini, PK, Funk, S, Thompson, RN

Publikováno v: The Lancet. Infectious diseases. 22(5)

Background In May, 2021, the delta (B.1.617.2) SARS-CoV-2 variant became dominant in the UK, superseded by the omicron (B.1.1.529) variant in December, 2021. The delta variant is associated with increased transmissibility compared with the alpha vari

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71131faa7f322e091086be4529c212e6
https://pubmed.ncbi.nlm.nih.gov/35176229

The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: A self-controlled case-series analysis

Autor: Stowe, J, Andrews, NJ, Turner, PJ, Miller, E

Kawasaki disease (KD) is an uncommon condition occasionally reported after childhood vaccination. Admissions with a KD-compatible diagnosis identified from a national database in England were linked to immunisation records to investigate the risk aft

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::5b21d27c8e88a25c74d7176783f1b8b6
https://researchonline.lshtm.ac.uk/id/eprint/4659429/1/Stowe-etal-2020_The-risk-of-Kawasaki-disease.pdf

Do delays in data availability limit the implementation of near real-time vaccine safety surveillance using the Clinical Practice Research Datalink?

Autor: Leite, A, Thomas, SL, Andrews, NJ

Near real-time vaccine safety surveillance (NRTVSS) using electronic health records has been used to detect timely vaccine safety signals. Trial implementation of NRTVSS using the Clinical Practice Research Datalink (CPRD) has shown that there is lim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::6ae44eb138640201d85c5308fced5403

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.

Autor: Trotter CL (AUTHOR), Andrews NJ (AUTHOR), Kaczmarski EB (AUTHOR), Miller E (AUTHOR), Ramsay ME (AUTHOR)

Publikováno v: Lancet. 7/24/2004, Vol. 364 Issue 9431, p365-367. 3p.